Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5817634 | 0.95 | TSHR (0.41) | TSHRDNM1THRBFAAHTRPV1 | |
| SCHEMBL28179466 | 0.93 | TSHR (0.43) | TSHRDNM1THRBFAAHTRPV1 | |
| SCHEMBL11246678 | 0.91 | TSHR (0.41) | TSHRDNM1THRBFAAHTRPV1 | |
| SCHEMBL28100004 | 0.91 | LMNA (0.38) | TSHRDNM1THRBALDH1A1LMNA | |
| SCHEMBL17336085 | 0.91 | TSHR (0.41) | TSHRDNM1THRBFAAHTRPV1 | |
| SCHEMBL7066232 | 0.91 | TSHR (0.41) | TSHRDNM1THRBFAAHTRPV1 | |
| SCHEMBL17336097 | 0.91 | TSHR (0.41) | TSHRDNM1THRBFAAHTRPV1 | |
| SCHEMBL10490298 | 0.91 | TSHR (0.41) | TSHRDNM1THRBFAAHTRPV1 | |
| SCHEMBL15902252 | 0.90 | TSHR (0.44) | TSHRDNM1THRBFAAHTRPV1 | |
| SCHEMBL21196910 | 0.90 | TSHR (0.44) | TSHRDNM1THRBFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897589-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-01 | — | — | US | disclosed |
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | PIR, SYMPK, P2RX5 | TSHR 3179/4885DNM1 1382/4885THRB 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.